Olema Pharmaceuticals, Inc.

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover

While Menarini Group / Stemline Therapeutics, Inc. ’s leading oral selective estrogen receptor degrader (SERD) Orserdu has got off to a strong start following its February launch for breast cancer, n

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

With investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue